Aegerion subpoena not a 'major surprise,' says Leerink Leerink views the Aegerion's subpoena from the U.S. Department of Justice as not a "major surprise" after the FDA reprimanded the company for statements made by its CEO on CNBC that suggested Juxtapid can improve patient survival, which has not been studied in clinical trial. The firm expects the subpoena will result in more rigorous marketing practices controlled by compliance and a “manageable fine" and reiterates an Outperform rating on Aegerion.
Aegerion price target lowered to $46 from $66 at Leerink Leerink lowered its price target for Aegerion shares to $46 after its survey of 40 U.S. cardiologists implied a more bearish outlook for Juxtapid once PCSK9s emerge. The firm, however, believes new patient adds are well outpacing Juxtapid discontinuations in the near term. It keeps an Outperform rating on the stock.